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INTRODUCTION 
Acute coronary syndrome (ACS) includes myocardial 
infarction with elevated ST segment, without elevated ST 
segment and unstable Angina.
1,2
 In America about 1.68 
million patients were diagnosed with ACS during 2001.
3
 
Chest pain has been the second major complaint in the 
emergency of North America's hospitals.
4
 Usually 10-
30% of the patients with chest pain have ACS. 1-4% of 
ACS and 2-3% of the MI patients are mistakenly 
discharged from hospitals.
5-6
 In Iran, cardiovascular 
disease, with 46% death rate, is the most common cause 
of death.
7
 Atherosclerosis of coronary has been the most 
important cause of heart diseases and the findings of the 
recent studies showed that the inflammatory process 
involved in atherosclerosis is one of the most important 
molecular mechanisms.
8-11
  
ABSTRACT 
 
Background: Findings of other researches indicate that inflammation process is one of the most important molecular 
interactions mediated in atherosclerosis and the inflammation indexes of plasma level such as high-sensitivity C-
reactive protein (hs-CRP) is regarded to predict the risk of cardio-vascular diseases. According to various studies, 
statins are certainly effective in the prevention of atherosclerosis and anti-inflammatory role of atorvastatin by 
lowering effect on hs-CRP can be considered. The aim of this study was to compare the effect of high and low doses 
of atorvastatin on levels of hs-CRP in patients with acute coronary syndrome. 
Methods: This is a clinical trial study that has been done on 180 patients with acute coronary syndrome who referred 
to Imam Khomeini hospital in Ardabil. Patients were divided in 2 groups randomly. Atorvastatin with low dose 
(20mg) and high dose (40mg) with routine treatments were given to first and second groups, respectively. The hs-
CRP level was evaluated for all patients in hospitalized time and third month late. Data were collected and analyzed 
by statistical methods in SPSS.19. 
Results: Of all patients, 40 patients (22.2%) was assayed with STEMI, 8 patients (4.4%) with N/Q WMI and132 
patients (73.3%) with U/A. 125 patients (69.4%) were male and rest of them were female. The age average of patients 
was 59.1±8.1 years. 74 (41.1%) of patients had blood pressure and 35 (19.4%) use smoke. After three months, in 
group with low dose, 81 patients (90%) and in group with high dose 85 patients (94.4%) improved. The atorvastatin 
with high dose could significantly decrease the hs-CRP ratio with 40% more than other group with 13.3%. 
Conclusions: In this study high dosage of atorvastatin could lessen significantly the hs-CRP and LDL ratio compared 
to atorvastatin with low dosage. 
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In this regard, the relationship between plasma levels of 
inflammatory markers has been considered in order to 
predict the risk of cardiovascular diseases. Cytokines, 
pro-atherogenic enzymes and CRP can be noted as 
Inflammatory markers which can be directly released 
from inflammatory cells and found in the platelets and 
tissues exposed to ischemia.
12
 Hs-CRP is an acute phase 
protein is made in the liver under the control of serum 
concentrations of IL6 during the inflammatory process. In 
cases with low CRP levels that cannot be qualitatively 
revealed by symbol “+”, it can be found by measuring of 
hs-CRP levels in blood.
13
  
Different epidemiological studies have shown that plasma 
levels of hs-CRP is an independent and strong marker for 
determine the risk of heart attacks and peripheral artery 
diseases.
13-15 Statins are the inhibitors of Reductase 
HMG-COA enzyme that is essential for the synthesis of 
cholesterol and among the existing statins in Iran, 
atorvastatin is more efficiency than others. Anti-
inflammatory effects of statins in lowering hs-CRP can 
have an important role in the treatment of ACS patients.
16  
The research findings show that the process of 
inflammation is one of the molecular mechanisms 
involved in atherosclerosis and in this regard plasma 
levels of inflammatory markers such as hs-CRP have 
been considered in order to predict the risk of 
cardiovascular disease. According to various studies, 
statins are certainly effective in the prevention of 
atherosclerosis and anti-inflammatory role of atorvastatin, 
by its lowering effect on hs-CRP, can be considered. The 
aim of this study was to compare the effect of high and 
low doses of atorvastatin on hs-CRP levels in patients 
with ACS.  
METHODS 
This clinical trial study was conducted on 180 patients, 
with acute coronary syndrome, that referred to Imam 
Khomeini hospital in Ardebil city. Patients were 
randomly divided into two groups. Along with routine 
treatments, low-dose atorvastatin in the first group 
(20mg) and high-dose atorvastatin in the second group 
(40 mg) was administered.  
The patients were followed for 12 weeks and hs-CRP 
levels of the patients were measured on admission and 
three months later. The data were collected by using a 
checklist containing some questions about demographic 
data, risk factors for heart disease (such as high blood 
pressure, diabetes, hyperlipidemia, smoking, opioids and 
alcohol, and family history of heart disease in the patient 
and his relatives), the levels of primary and secondary hs-
CRP, the levels of primary and secondary HDL and LDL. 
The collected data were analyzed using statistical 
methods in statistical software spss version 19.  
RESULTS 
Of the total patients, 40 patients (22.2%) with STEMI, 8 
patients (4.4%) with the N / Q WMI and 132 patients 
(73/3%) with U/A were evaluated. 67 patients (74.4%) in 
the group receiving low-dose atorvastatin and 65 patients 
(72.2%) in the high-dose atorvastatin receiving group had 
unstable angina. The two groups were matched in terms 
of gender.  
The average age in the group receiving low-dose 
atorvastatin was 60.6±7.9 and in the group receiving 
high-dose atorvastatin was 57.6±8.1 years (Table 1).
 
Table 1: Changes in mean of hs-CRP level before and after intervention. 
p-value 
hs-CRP decreasing 
rate (%) 
hs-CRP(mg/L) Time Groups 
0.001 
40 
4±2.5 hs-CRP in baseline 
Atorvastatin high dose 
2.4±1.8 hs-CRP after three month 
13.3 
3.03±2.53 hs-CRP in baseline 
Atorvastatin low dose 
2.6±2.58 hs-CRP after three month 
Table 2: Changes in LDL level during study in two groups. 
p-value HDL decreasing rate (%) HDL Time Groups 
0.001 9 37.3±3.95 First (mean) Atorvastatin high dose 
40.8±4.7 Second (mean) 
6 38.8±3.8 First (mean) Atorvastatin low dose 
41.4±3.9 Second (mean) 
 
There wasn’t any significant difference between the two 
groups in terms of hypertension, diabetes, 
hyperlipidemia, history of PCI, CABG, CAG, smoking 
and ACS history in family.   
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After a three-month follow-up period it was observed that 
in the group receiving low-dose atorvastatin, 81 patients 
(90%) were well, 8 patients (8.9%) again were suffering 
from ACS and one patient died. While in the group 
receiving high-dose atorvastatin, 85 patients (94.4%) 
were well and 5 patients again were suffering from ACS. 
There was no significant relation in the impact of high 
and low doses of Atorvastatin on the patient's clinical 
process. Also in baseline, Echo of patients was performed 
and ejection fraction for patients was calculated. Among 
the groups receiving low-dose atorvastatin, 72 patients 
(80 %) had normal EF and 18 patients (20%) had reduced 
EF. In the group receiving high-dose atorvastatin, 66 
patients (73.3%) had normal EF and 24 patients (26.7%) 
had reduced EF and there was no significant difference 
between two groups.  
 
Table 3: Changes in HDL level during study in two groups. 
p-value LDL decreasing rate (%) LDL Time Groups 
0.001 23 104.9±14.5 First (mean) Atorvastatin high dose 
82.1±10.84 Second (mean) 
10 95.8±13.8 First (mean) Atorvastatin low dose 
79.5±13.4 Second (mean) 
 
The high-dose atorvastatin reduced the amount of hs-
CRP about 40 %, while low-dose atorvastatin only 13.3% 
reduced the hs-CRP level and the difference was 
statistically significant (p=0.001) (Table 2).  
It was also observed that atorvastatin at a low dose could 
only reduce the amount of LDL about 10 %, while 
atorvastatin at high dose could reduce LDL about 23% 
and the difference was statistically significant between 
two groups (P = 0.001) (Table 2). Also, the low-dose 
atorvastatin could increase HDL levels about 6% while 
high-dose atorvastatin reduced this amount about 9 % and 
the difference was statistically significant (P = 0.009) 
(Table 3). 
In this study, no significant relationship was found 
between the level of hs-CRP and prognosis of the 
patients. 
DISCUSSION 
In this study of the total patients, 40 patients (22.2%) 
with STEMI, 8 patients (4.4%) with the N / Q WMI and 
132 patients (73/3%) with U/A were evaluated which was 
different with other study results.
17-18
 Unstable angina and 
myocardial infarction in patients who are hospitalized 
with acute coronary syndrome varies according to 
different studies. The ratio of patients with unstable 
angina to MI in our study was 3.3 to 1 which upper than 
other studies. This results perhaps because of more 
sensitive methods of measuring biochemical markers of 
myocardial necrosis such as troponin and CK_MB.
17-24
 
In this study, there wasn’t significant relationship 
between sex and the risk of acute coronary syndrome, the 
occurrence of unstable angina and QWMI. Meanwhile, 
various studies have different results.  
The most obvious biological explanation for differences 
related to sex is coronary heart disease (CHD) 
demonstration.
25-28
 The possible cause of the 
insignificancy of gender in this study can be attributed to 
the small sample size. In this study, no relationship was 
observed between the history of PCI, CABG and CAG 
with gender.  
A study has shown that the percentage of men who 
undergo subcutaneous coronary angiography and 
angioplasty are significantly higher than women.
28 Also 
Jones in a review article in 2003 stated that men are 
referred for coronary angiography two times more than 
women. He also states that non-specific symptoms in 
women and failure to early detection of patients leads to a 
delay in receiving appropriate treatment.
29
  
In this study, high-dose atorvastatin significantly 
increased HDL and decreased LDL levels, which was 
consistent with other similar studies.
30-32
 In this study, 
consumption of high-dose statins could significantly 
reduce the amount of hs-CRP compared to lower doses. 
Meanwhile, in the studies conducted by Macin and 
Vasilieva it was revealed that CRP level in ACS 
decreased quickly after taking atorvastatin.
33
  
In Gupta's study, atorvastatin significantly reduced the 
levels of hs-CRP and followed by the platelet aggregation 
in patients with high hs-CRP level.Also, in Gupta's study 
it was observed that in the group receiving atorvastatin 
the reduction of the level of hs-CRP was significantly 
more than the group who did not receive the medicine. 
After reviewing the study performed by Boon-
baichaiapruck, it was observed that atorvastatin reduced 
LDL level about 44% and hs-CRP level about 10%, 
which was statistically significant (p=0.003).
34 
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CONCLUSION  
Results showed that although high-doses atorvastatin 
compared to the low-doses, significantly reduced LDL 
and hs-CRP levels but high-dose atorvastatin 
administration couldn't have more acceptable effects on 
the patient’s clinical treatment and also prevent repeated 
ACD.  
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